Vol 51 No 02

"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.

One factor is whether dissection was performed for staging or for therapeutic purposes.

“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.

Established patients with chronic problems may push back against charges.

"What I hope to see next year is continuing improvement in standards of care when we’re talking about [prostate-specific antigen] screening and prostate cancer diagnosis and treatment," says urologist Michael Cox, MD.

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

"The patient’s counsel alleged that the urologist had failed to properly inform the patient of the risks and complications associated with the treatment," writes Acacia Brush Perko, Esq.

"Unfortunately, there is no 'one size fits all' answer to when you should start receiving Social Security benefits," writes Jeff Witz, CFP.

Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.

Amanda North, MD, discusses the AUA census in depth, specifically highlighting the data collected on residents and fellows.